Purdue To Market Palladone With Fewer Reps After Halving Sales Force
Executive Summary
Purdue will promote Palladone (hydromorphone extended-release) with significantly fewer reps after laying off half its sales force
You may also be interested in...
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events
Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates
FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events
“Authorized” Generic Opponents Turn To State Laws After Federal Court Loss
Generic companies are pursuing alternative litigation routes in their efforts to block "authorized" generics following a Washington, D.C. appeals court decision upholding FDA's current policy on the products